Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors
L Campana(University of Padua), A Bonadies(San Gallicano Hospital), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Paolo Curatolo(Sapienza University of Rome), Gian Luca De Salvo(Istituto Oncologico Veneto), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michele Guida(Istituto Tumori Bari), Lorenzo Borgognoni(Tumour Institute of Tuscany), Pietro Quaglino(Department of Medical Sciences), Simone Mocellin(University of Padua), Massimo Framarini(Ospedale G.B. Morgagni - L.Pierantoni), Federica Marenco(University Dermatology), Roberta Rotunno(Sapienza University of Rome), S. Bucher(San Gallicano Hospital), Angela De Paoli, Nicola Mozzillo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carlo Riccardo Rossi(University of Padua)
Cited by 119
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k